Glofitamab, venetoclax, and lenalidomide combination shows promising efficacy in high-risk mantle cell lymphoma
Glofitamab, venetoclax, and lenalidomide combination shows promising efficacy in high-risk mantle cell lymphoma
Ropeginterferon alfa-2b is evaluated as a disease-modifying option in essential thrombocythemia
Fixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLL
IP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor-associated thrombosis
AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer
AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab
New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights blinatumomab benefits in key high-risk molecular types
Tec-Dara significantly improves PFS and OS compared to SoC in relapsed/refractory multiple myeloma
Black patients show inferior survival despite similar cytogenetics and treatment response
Asciminib shows high molecular response, favourable safety in 2L CML-CP
Rocbrutinib shows strong responses in resistant CLL, including BTKi- and venetoclax-exposed patients
First-line use of tepotinib in METex14 NSCLC: A patient-centered journey